Despite protests from the pharma industry, California Gov. Jerry Brown has decided to sign legislation aimed at increasing transparency in pricing.

BDO sifted through SEC filings to discover just what the top 100 life sciences companies are most worried about these days.

Flexion's Zilretta won approval on Friday, with its official label winning praise from executives and analysts.

Sen. Claire McCaskill is moving to shut down the "brazen loophole" exposed in Allergan's tribal licensing deal.

Novartis is only in the very early days of its Kymriah rollout in the U.S., but company executives aren't only focusing on the States.

As the EMA prepares to move, officials have unveiled the list of cities staffers say would keep them around.

FDA Commissioner Scott Gottlieb, M.D., is embarking on a series of initiatives aimed directly at bringing down rising drug prices, specifically for “complex…

The generic drug industry's effort for relief against Maryland pricing regulations has come up short, at least for now.

For Novo Nordisk and its new fast-acting mealtime insulin, a second try at the FDA gatekeepers was enough to secure an approval.

Rep. Elijah Cummings, D-Md., is urging President Trump to press for lower prices on Biogen's multiple sclerosis drug Zinbryta.

Regulatory